Atypical Antipsychotics and Glucose Dysregulation: A Series of 4 Cases

Sanjay Gupta, M.D.; Barbara Lentz, R.N.; Kari Lockwood, R.N.; and Bradford Frank, M.D., M.P.H.

There have been reports in the psychiatric literature of the association of glucose dysregulation and diabetes mellitus with the use of atypical and typical (conventional) antipsychotics. We present a series of 4 additional cases in which psychotic disorders (DSM-IV) were treated with atypical antipsychotics, and patients subsequently developed glucose dysregulation or diabetes mellitus. The implications of these findings are discussed.

(Primary Care Companion J Clin Psychiatry 2001;3:61-65)

Received Feb. 1, 2001; accepted March 20, 2001. From the Departments of Psychiatry, Olean General Hospital and State University of New York Upstate Medical University Center at Syracuse (Dr. Gupta); the Department of Psychiatry, University of Buffalo, School of Medicine and Biomedical Sciences, Buffalo (Drs. Gupta and Frank); the Continuing Day Treatment Program, Olean, N.Y. (Ms. Lentz); the Psychiatric Network (Ms. Lockwood); and the Department of Psychiatry, WCA Hospital, Jamestown, N.Y. (Dr. Frank).

Financial disclosure: Dr. Gupta is a consultant for Eli Lilly; has received research/grant support from Eli Lilly, Janssen, and Abbott; has received honoraria from Eli Lilly, Janssen, Forest, and Pfizer; and is on the speaker or advisory boards of Eli Lilly, Janssen, and Forest.

Reprint requests to: Sanjay Gupta, M.D., 515 Main St., Olean, NY 14760 (e-mail: network1@eznet.net).